BioCentury
ARTICLE | Finance

More chips on CRISPR

Strategic investors SR One, Celgene enter gene editing via CRISPR Therapeutics

May 11, 2015 7:00 AM UTC

Unlike some of its gene-editing peers, CRISPR Therapeutics AG is keeping its strategic investors at arm's length - at least for now.

Late last month SR One, the venture arm of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), led a $35 million series A tranche in CRISPR Therapeutics, and Celgene Corp. (NASDAQ:CELG) subsequently led a $29 million series B round. ...